Patent intelligence · US
US 12296050
Pharmaceutical compositions comprising maralixibat and uses thereof
Pharmaceutical compositions comprising maralixibat and uses thereof
Patent details — US 12296050
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 13, 2025
- Expiration
- May 8, 2045
- Applicant
- MIRUM PHARMACEUTICALS, INC.
- Claims
- 28
- CPC classes
- A61K, A61K31/4995, A61K47/10, A61K47/12
Quick answer
US 12296050 (Pharmaceutical compositions comprising maralixibat and uses thereof) is held by MIRUM PHARMACEUTICALS, INC.. Status: granted. Granted May 13, 2025. Expires May 8, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- MIRUM PHARMACEUTICALS, INC.
- Grant date
- Expiration
- Claims
- 28
- CPC classes
- A61K, A61K31/4995, A61K47/10, A61K47/12, A61K47/183, A61K47/22
More from MIRUM PHARMACEUTICALS, INC.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 12296050?
US 12296050 (Pharmaceutical compositions comprising maralixibat and uses thereof) is held by MIRUM PHARMACEUTICALS, INC.. Status: granted. Granted May 13, 2025. Expires May 8, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12296050?
MIRUM PHARMACEUTICALS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 12296050 expire?
Our index shows an expiration date of May 8, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.